Results 81 to 90 of about 10,280 (206)

Exploring the Vasculitis‐Tumors Link: Epidemiological Patterns, Mechanistic Insights, and Clinical Implications

open access: yesAdvanced Science, Volume 13, Issue 14, 9 March 2026.
This review outlines association between vasculitis and malignancies and provides practical value for clinicians in distinguishing primary vasculitis from malignancy‐associated forms and optimizing patient surveillance, improving recognition of tumor‐associated vasculitis to reduce the risk of misdiagnosis, supporting more accurate clinical decision ...
Xiaofei Shi   +8 more
wiley   +1 more source

Granulomatosis With Polyangiitis Presenting as Deep Vein Thrombosis in an Adolescent: A Rare Case Report

open access: yesClinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Granulomatosis with polyangiitis can rarely present as deep vein thrombosis in adolescents. Unexplained thrombosis in a young patient, accompanied by systemic inflammatory features, should raise suspicion for an underlying vasculitis. Early recognition and prompt initiation of immunosuppressive therapy alongside anticoagulation are crucial to ...
Bishal Budha   +8 more
wiley   +1 more source

The Impact of Estrogen on Stromal Elements in the Proximal Airway in Idiopathic Subglottic Stenosis

open access: yesThe Laryngoscope, Volume 136, Issue 3, Page 1349-1356, March 2026.
ABSTRACT Objectives Idiopathic subglottic stenosis (iSGS) is an unexplained fibrosis of the proximal airway that predominantly impacts Caucasian women. Clinically, premenopausal patients suffer from higher recurrence rates, potentially implicating ovarian hormone 17B‐estradiol (E2) in disease pathogenesis.
Emily L. Mace   +13 more
wiley   +1 more source

Intracerebral hemorrhage after IV tPA for stroke as early symptom of ANCA-associated vasculitis

open access: yeseNeurologicalSci, 2017
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are rare diseases characterized by a necrotizing small-vessel vasculitis and circulating ANCA that comprise granulomatosis with polyangiitis, microscopic polyangiitis, and ...
Neda Zarghami Esfahani   +3 more
doaj   +1 more source

The Drug Safety Framework of Avacopan: A Pharmacovigilance Study

open access: yesMedicine Advances, Volume 4, Issue 1, Page 77-89, March 2026.
We identified 11 previously unreported potential adverse events associated with avacopan. No high‐priority clinical events were observed; however, special attention should be paid to the potential possibility of avacopan‐induced vanishing bile duct syndrome (Logos and icons displayed in the sections “Safety Framework” and “Data Sources and ...
Tianqi Chang   +4 more
wiley   +1 more source

Clinical presentation and outcome of pediatric ANCA-associated glomerulonephritis [PDF]

open access: yes, 2016
Background Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a small- and medium-sized vasculitis classically seen in adult patients, with peak onset near the fifth to seventh decade of life.
Andreoli, Sharon P., Kouri, Anne M.
core   +1 more source

Certified reference material against PR3 ANCA IgG autoantibodies. From development to certification. [PDF]

open access: yes, 2018
Background The importance of the standardisation of immunoassays for autoantibodies has been widely discussed. The appropriate use of certified reference materials (CRM) could contribute to a more accurate diagnosis and follow-up of a series of diseases ...
Committee for the Harmonisation of Autoimmune Testing (C-HAT) of   +6 more
core   +1 more source

A Rare Case of Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis Presenting as Pyelonephritis [PDF]

open access: yesJournal of Clinical and Diagnostic Research
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV) is a condition affecting small and medium-sized vessels, predominantly impacting the kidneys.
Chetan Phadke, Shreeharsh Godbole
doaj   +1 more source

Therapeutic advances in the treatment of vasculitis [PDF]

open access: yes, 2016
Considerable therapeutic advances for the treatment of vasculitis of the young have been made in the past 10 years, including the development of outcome measures that facilitate clinical trial design.
Brogan, PA, Eleftheriou, D
core   +2 more sources

Home - About - Disclaimer - Privacy